Use of polyclonal/monoclonal antibody therapies in transplantation

References

• Yeung MY, Najafian N, Sayegh MH. Targeting CD28 to prevent transplant rejection. Expert Opin Ther Targets. 2014;18:225–242.
   PubMed Web of Science ®Google Scholar
• Hardinger KL, Schnitzler MA, Miller B, et al. Five-year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation. 2004;78:136–141.
   PubMed Web of Science ®Google Scholar
• Hardinger KL, Rhee S, Buchanan P, et al. A prospective, randomized, double-blinded comparison of thymoglobulin versus ATGAM for induction immunosuppressive therapy: 10-year results. Transplantation. 2008;86:947–952.
   PubMed Web of Science ®Google Scholar
• Popow I, Leitner J, Grabmeier-Pfistershammer K, et al. A comprehensive and quantitative analysis of the major specificities in rabbit antithymocyte globulin preparations. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2013;13:3103–3113.
   PubMed Web of Science ®Google Scholar
• Michallet MC, Preville X, Flacher M, et al. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation. 2003;75:657–662.
   PubMed Web of Science ®Google Scholar
• Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007;21:1387–1394.
   PubMed Web of Science ®Google Scholar
• Bonnefoy-Berard N, Genestier L, Flacher M, et al. Apoptosis induced by polyclonal antilymphocyte globulins in human B-cell lines. Blood. 1994;83:1051–1059.
   PubMed Web of Science ®Google Scholar
• Zand MS, Vo T, Huggins J, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation. 2005;79:1507–1515.
   PubMed Web of Science ®Google Scholar
• Bonnefoy-Berard N, Revillard JP. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant. 1996;15:435–442.
   PubMed Web of Science ®Google Scholar
• Genestier L, Fournel S, Flacher M, et al. Induction of fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood. 1998;91:2360–2368.
   PubMed Web of Science ®Google Scholar
• Zand MS, Vo T, Pellegrin T, et al. Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin. Blood. 2006;107:2895–2903.
   PubMed Web of Science ®Google Scholar
• Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation. 1995;59:1194–1200.
   PubMed Web of Science ®Google Scholar
• Preville X, Flacher M, LeMauff B, et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation. 2001;71:460–468.
   PubMed Web of Science ®Google Scholar
• Beiras-Fernandez A, Chappell D, Hammer C, et al. Impact of polyclonal anti-thymocyte globulins on the expression of adhesion and inflammation molecules after ischemia-reperfusion injury. Transpl Immunol. 2009;20:224–228.
   PubMed Web of Science ®Google Scholar
• Chappell D, Beiras-Fernandez A, Hammer C, et al. In vivo visualization of the effect of polyclonal antithymocyte globulins on the microcirculation after ischemia/reperfusion in a primate model. Transplantation. 2006;81:552–558.
   PubMed Web of Science ®Google Scholar
• Lopez M, Clarkson MR, Albin M, et al. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrology: JASN. 2006;17:2844–2853.
   PubMed Web of Science ®Google Scholar
• Feng X, Kajigaya S, Solomou EE, et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood. 2008;111:3675–3683.
   PubMed Web of Science ®Google Scholar
• Hale G, Bright S, Chumbley G, et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood. 1983;62(4):873–882..
   PubMed Web of Science ®Google Scholar
• Hale G, Dyer MJ, Clark MR, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet. 1988;2:1394–1399.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, O’Brien S, Keating MJ. Alemtuzumab: a novel monoclonal antibody. Expert Opin Biol Ther. 2001;1:1059–1065.
   PubMed Web of Science ®Google Scholar
• Nuckel H, Frey UH, Roth A, et al. Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. Eur J Pharmacol. 2005;514:217–224.
   PubMed Web of Science ®Google Scholar
• Stanglmaier M, Reis S, Hallek M. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol. 2004;83:634–645.
   PubMed Web of Science ®Google Scholar
• Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation. 2003;76:120–129.
   PubMed Web of Science ®Google Scholar
• Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2005;5:465–474.
   PubMed Web of Science ®Google Scholar
• Davison GM, Novitzky N, Kline A, et al. Immune reconstitution after allogeneic bone marrow transplantation depleted of T cells. Transplantation. 2000;69:1341–1347.
   PubMed Web of Science ®Google Scholar
• Thomas PG, Ishihara K, Vaidya S, et al. Campath and renal transplant rejection. Clin Transplant. 2004;18:759–761.
   PubMed Web of Science ®Google Scholar
• Albitar M, Do KA, Johnson MM, et al. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer. 2004;101:999–1008.
   PubMed Web of Science ®Google Scholar
• Gaulton GN, Markmann JF. Regulation of lymphocyte growth by antagonists of interleukin-2 or its cellular receptor. Immunol Res. 1988;7:113–135.
   PubMed Web of Science ®Google Scholar
• Amlot PL, Rawlings E, Fernando ON, et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation. 1995;60:748–756.
   PubMed Web of Science ®Google Scholar
• Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. daclizumab triple therapy study group. N Engl J Med. 1998;338:161–165.
   PubMed Web of Science ®Google Scholar
• Bluestone JA, Liu W, Yabu JM, et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2008;8:2086–2096.
   PubMed Web of Science ®Google Scholar
• KDIGO clinical practice guideline for the care of kidney transplant recipients. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2009;9(Suppl 3):S1–155.
   Google Scholar
• Webster AC, Ruster LP, McGee R, et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev. 2010;(1):CD003897.
   PubMed Web of Science ®Google Scholar
• Hellemans R, Bosmans JLL, Abramowicz D. Induction therapy for kidney transplant recipients: do we still need anti-il2 receptor monoclonal antibodies? Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2017;17:22–27. doi: 10.1111/ajt.13884
   Google Scholar
• Webster A, Woodroffe RC, Taylor RS, et al. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev. 2005;(4):CD003961.
   Google Scholar
• Silva HT Jr., Yang HC, Abouljoud M, et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2007;7:595–608.
   PubMed Web of Science ®Google Scholar
• Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357:2562–2575.
   PubMed Web of Science ®Google Scholar
• Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2004;4:378–383.
   PubMed Web of Science ®Google Scholar
• Rostaing L, Charpentier B, Glyda M, et al. Alefacept combined with tacrolimus, mycophenolate mofetil and steroids in de novo kidney transplantation: a randomized controlled trial. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2013;13:1724–1733.
   PubMed Web of Science ®Google Scholar
• Albano L, Banas B, Klempnauer JL, et al. OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation. Transplantation. 2013;96:897–903.
   PubMed Web of Science ®Google Scholar
• Tanriover B, Jaikaransingh V, MacConmara MP, et al. Acute rejection rates and graft outcomes according to induction regimen among recipients of kidneys from deceased donors treated with tacrolimus and mycophenolate. Clin Journal Am Soc Nephrology: CJASN. 2016;11:1650–1661.
   PubMed Web of Science ®Google Scholar
• Hart A, Smith JM, Skeans MA, et al. Kidney. Am J Transplant. 2016;16:11–46.
   PubMed Web of Science ®Google Scholar
• Willoughby LM, Schnitzler MA, Brennan DC, et al. Early outcomes of thymoglobulin and basiliximab induction in kidney transplantation: application of statistical approaches to reduce bias in observational comparisons. Transplantation. 2009;87:1520–1529.
   PubMed Web of Science ®Google Scholar
• Mourad G, Garrigue V, Squifflet JP, et al. Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation. 2001;72:1050–1055.
   PubMed Web of Science ®Google Scholar
• Ahsan N, Holman MJ, Jarowenko MV, et al. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2002;2:568–573.
   PubMed Web of Science ®Google Scholar
• Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of thymoglobulin versus ATGAM for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation. 1999;67:1011–1018.
   PubMed Web of Science ®Google Scholar
• Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006;355:1967–1977.
   PubMed Web of Science ®Google Scholar
• Brennan DC, Schnitzler MA. Long-term results of rabbit antithymocyte globulin and basiliximab induction. N Engl J Med. 2008;359:1736–1738.
   PubMed Web of Science ®Google Scholar
• Lentine KL, Schnitzler MA, Xiao H, et al. Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10-10 study participants. Trials. 2015;16:365.
   PubMed Web of Science ®Google Scholar
• Pilch NA, Taber DJ, Moussa O, et al. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation. Ann Surg. 2014;259:888–893.
   PubMed Web of Science ®Google Scholar
• Hellemans R, Hazzan M, Durand D, et al. Daclizumab versus rabbit antithymocyte globulin in high-risk renal transplants: five-year follow-up of a randomized study. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2015;15:1923–1932.
   PubMed Web of Science ®Google Scholar
• Group C, Haynes R, Harden P, et al. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. Lancet (London, England). 2014;384:1684–1690.
   PubMed Web of Science ®Google Scholar
• Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation–efficacy and safety at five years. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2005;5:1347–1353.
   PubMed Web of Science ®Google Scholar
• Gralla J, Wiseman AC. The impact of IL2ra induction therapy in kidney transplantation using tacrolimus- and mycophenolate-based immunosuppression. Transplantation. 2010;90:639–644.
   PubMed Web of Science ®Google Scholar
• Lim WH, Chadban SJ, Campbell S, et al. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients. Nephrology. 2010;15:368–376.
   PubMed Web of Science ®Google Scholar
• Tanriover B, Zhang S, MacConmara M, et al. Induction therapies in live donor kidney transplantation on tacrolimus and mycophenolate with or without steroid maintenance. Clin Journal Am Soc Nephrology: CJASN. 2015;10:1041–1049.
   PubMed Web of Science ®Google Scholar
• Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008;248:564–577.
   PubMed Web of Science ®Google Scholar
• Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med. 2011;364:1909–1919.
   PubMed Web of Science ®Google Scholar
• Louis S, Audrain M, Cantarovich D, et al. Long-term cell monitoring of kidney recipients after an antilymphocyte globulin induction with and without steroids. Transplantation. 2007;83:712–721.
   PubMed Web of Science ®Google Scholar
• Waller EK, Langston AA, Lonial S, et al. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant. 2003;9:460–471.
   PubMed Web of Science ®Google Scholar
• Ciancio G, Gaynor JJ, Guerra G, et al. Randomized trial of three induction antibodies in kidney transplantation: long-term results. Transplantation. 2014;97:1128–1138.
   PubMed Web of Science ®Google Scholar
• Lebranchu Y, Bridoux F, Buchler M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2002;2:48–56.
   PubMed Web of Science ®Google Scholar
• Farney AC, Doares W, Rogers J, et al. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation. 2009;88:810–819.
   PubMed Web of Science ®Google Scholar
• Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2004;4:611–620.
   PubMed Web of Science ®Google Scholar
• Helantera I, Lautenschlager I, Koskinen P. Prospective follow-up of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients. Nephrology, Dialysis, Transplantation: Official Publication Eur Dial Transpl Assoc Eur Ren Assoc. 2009;24:316–320.
   PubMed Web of Science ®Google Scholar
• Jamil B, Nicholls KM, Becker GJ, et al. Influence of anti-rejection therapy on the timing of cytomegalovirus disease and other infections in renal transplant recipients. Clin Transplant. 2000;14:14–18.
   PubMed Web of Science ®Google Scholar
• Lawen JG, Davies EA, Mourad G, et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation. 2003;75:37–43.
   PubMed Web of Science ®Google Scholar
• Ozaki KS, Pestana JO, Granato CF, et al. Sequential cytomegalovirus antigenemia monitoring in kidney transplant patients treated with antilymphocyte antibodies. Transpl Infectious Disease: Official Journal Transplant Soc. 2004;6:63–68.
   PubMedGoogle Scholar
• Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis. 2009;48:772–786.
   PubMed Web of Science ®Google Scholar
• Luan FL, Samaniego M, Kommareddi M, et al. Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients. Transpl Infectious Disease: Official Journal Transplant Soc. 2010;12:473–479.
   PubMed Web of Science ®Google Scholar
• Schadde E, D’Alessandro AM, Knechtle SJ, et al. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death. Transpl International: Official Journal Eur Soc Transplant. 2008;21:625–636.
   PubMed Web of Science ®Google Scholar
• Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2004;4:222–230.
   PubMed Web of Science ®Google Scholar
• Dharnidharka VR, Stevens G. Risk for post-transplant lymphoproliferative disorder after polyclonal antibody induction in kidney transplantation. Pediatr Transplant. 2005;9:622–626.
   PubMed Web of Science ®Google Scholar
• Caillard S, Lelong C, Pessione F, et al. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French registry. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2006;6:2735–2742.
   PubMed Web of Science ®Google Scholar
• Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2013 annual data report: kidney. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2015;15(Suppl 2):1–34.
   PubMed Web of Science ®Google Scholar
• Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infectious Disease: Official Journal Transplant Soc. 2001;3:70–78.
   PubMedGoogle Scholar
• Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation. 2003;76:984–988.
   PubMed Web of Science ®Google Scholar
• Caillard S, Dharnidharka V, Agodoa L, et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation. 2005;80:1233–1243.
   PubMed Web of Science ®Google Scholar
• Bustami RT, Ojo AO, Wolfe RA, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2004;4:87–93.
   PubMed Web of Science ®Google Scholar
• Funch DP, Walker AM, Schneider G. Ganciclovir and Acyclovir reduce the risk of post-Transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant. 2005;5(12):2894–2900.
   PubMed Web of Science ®Google Scholar
• Marks WH, Ilsley JN, Dharnidharka VR. Posttransplantation lymphoproliferative disorder in kidney and heart transplant recipients receiving thymoglobulin: a systematic review. Transplant Proc. 2011;43:1395–1404.
   PubMed Web of Science ®Google Scholar
• Hall EC, Engels EA, Pfeiffer RM, et al. Association of antibody induction immunosuppression with cancer after kidney transplantation. Transplantation. 2015;99:1051–1057.
   PubMed Web of Science ®Google Scholar
• Guttmann RD, Caudrelier P, Alberici G, et al. Pharmacokinetics, foreign protein immune response, cytokine release, and lymphocyte subsets in patients receiving thymoglobuline and immunosuppression. Transplant Proc. 1997;29:24S–26S.
   PubMed Web of Science ®Google Scholar
• Moreau T, Coles A, Wing M, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain. 1996;119(Pt 1):225–237.
   PubMed Web of Science ®Google Scholar
• Clatworthy MR, Sivaprakasam R, Butler AJ, et al. Subcutaneous administration of alemtuzumab in simultaneous pancreas-kidney transplantation. Transplantation. 2007;84:1563.
   PubMed Web of Science ®Google Scholar
• Tanriover B, Chuang P, Fishbach B, et al. Polyclonal antibody-induced serum sickness in renal transplant recipients: treatment with therapeutic plasma exchange. Transplantation. 2005;80:279–281.
   PubMed Web of Science ®Google Scholar
• Boothpur R, Hardinger KL, Skelton RM, et al. Serum sickness after treatment with rabbit antithymocyte globulin in kidney transplant recipients with previous rabbit exposure. Am J Kidney Dis. 2010;55:141–143.
   PubMed Web of Science ®Google Scholar
• Pescovitz MD, Knechtle S, Alexander SR, et al. Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. Pediatr Transplant. 2008;12:447–455.
   PubMed Web of Science ®Google Scholar
• Lilliu H, Brun-Strang C, Le Pen C, et al. Cost-minimization study comparing simulect vs. thymoglobulin in renal transplant induction. Clin Transplant. 2004;18:247–253.
   PubMed Web of Science ®Google Scholar
• Oflazoglu E, Audoly LP. Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. Mabs. 2010;2:14–19.
   PubMed Web of Science ®Google Scholar
• Franks SE, Getahun A, Hogarth PM, et al. Targeting B cells in treatment of autoimmunity. Curr Opin Immunol. 2016;43:39–45.
   PubMed Web of Science ®Google Scholar
• Glennie MJ, French RR, Cragg MS, et al. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44:3823–3837.
   PubMed Web of Science ®Google Scholar
• Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2003;21:3940–3947.
   PubMed Web of Science ®Google Scholar
• Thaunat O, Patey N, Gautreau C, et al. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy. Transplantation. 2008;85:1648–1653.
   PubMed Web of Science ®Google Scholar
• Kamburova EG, Koenen H, Borgman KJE, et al. A single dose of rituximab does not deplete b cells in secondary lymphoid organs but alters phenotype and function. Am J Transplant. 2013;13:1503–1511.
   PubMed Web of Science ®Google Scholar
• Manshouri T, Do KA, Wang X, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood. 2003;101:2507–2513.
   PubMed Web of Science ®Google Scholar
• Beers SA, French RR, Chan HT, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood. 2010;115:5191–5201.
   PubMed Web of Science ®Google Scholar
• Clatworthy MR, Watson CJ, Plotnek G, et al. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med. 2009;360:2683–2685.
   PubMed Web of Science ®Google Scholar
• Chandraker A KJ, Stehlik J, Givertz M, et al. Rituximab induction in cardiac transplantation is associated with accelerated coronary artery vasculopathy: CTOT11. [abstract]. Am J Transplant. 2016;16(suppl 3).
   Web of Science ®Google Scholar
• Allergy, N.I.o., Diseases, I., National Heart, L., Institute, B., Transplantation, C.T.i.O., and Genentech, I. 2011. Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation. https://ClinicalTrials.gov/show/NCT01278745.
   Google Scholar
• van den Hoogen MW, Kamburova EG, Baas MC, et al. Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2015;15:407–416.
   PubMed Web of Science ®Google Scholar
• Tyden G, Ekberg H, Tufveson G, et al. A randomized, double-blind, placebo-controlled study of single dose rituximab as induction in renal transplantation: a 3-year follow-up. Transplantation. 2012;94:e21–22.
   PubMed Web of Science ®Google Scholar
• Ding Q, Yeung M, Camirand G, et al. Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. J Clin Invest. 2011;121:3645–3656.
   PubMed Web of Science ®Google Scholar
• Yeung MY, Ding Q, Brooks CR, et al. TIM-1 signaling is required for maintenance and induction of regulatory B cells. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2015;15:942–953.
   PubMed Web of Science ®Google Scholar
• Clatworthy MR, Friend PJ, Calne RY, et al. Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up. Transplantation. 2009;87:1092–1095.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 1998;16:2825–2833.
   PubMed Web of Science ®Google Scholar
• Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50:2580–2589.
   PubMed Web of Science ®Google Scholar
• Rosengren S, Wei N, Kalunian KC, et al. CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. Rheumatology. 2011;50:603–610.
   PubMed Web of Science ®Google Scholar
• Smith KG, Jones RB, Burns SM, et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum. 2006;54:2970–2982.
   PubMed Web of Science ®Google Scholar
• Ahuja A, Shupe J, Dunn R, et al. Depletion of B cells in murine lupus: efficacy and resistance. J Immunology. 2007;179:3351–3361.
   PubMed Web of Science ®Google Scholar
• Albert D, Dunham J, Khan S, et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis. 2008;67:1724–1731.
   PubMed Web of Science ®Google Scholar
• Genberg H, Hansson A, Wernerson A, et al. Pharmacodynamics of rituximab in kidney allotransplantation. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2006;6:2418–2428.
   PubMed Web of Science ®Google Scholar
• Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31:456–473.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Emery P, Bingham CO, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010;37:558–567.
   PubMed Web of Science ®Google Scholar
• Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2008;8:753–760.
   PubMed Web of Science ®Google Scholar
• Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus ATGAM in the treatment of acute graft rejection episodes after renal transplantation. Transplantation. 1998;66:29–37.
   PubMed Web of Science ®Google Scholar
• Basu A, Ramkumar M, Tan HP, et al. Reversal of acute cellular rejection after renal transplantation with Campath-1H. Transplant Proc. 2005;37:923–926.
   PubMed Web of Science ®Google Scholar
• Mao Q, Terasaki PI, Cai J, et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2007;7:864–871.
   PubMed Web of Science ®Google Scholar
• Zeng Q, Ng YH, Singh T, et al. B cells mediate chronic allograft rejection independently of antibody production. J Clin Invest. 2014;124:1052–1056.
   PubMed Web of Science ®Google Scholar
• Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2009;9:2532–2541.
   PubMed Web of Science ®Google Scholar
• Halloran PF, Pereira AB, Chang J, et al. Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: an international prospective study (INTERCOM). Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2013;13:2865–2874.
   PubMed Web of Science ®Google Scholar
• Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013;369:1215–1226.
   PubMed Web of Science ®Google Scholar
• Kim M, Martin ST, Townsend KR, et al. Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options. Pharmacotherapy. 2014;34:733–744.
   PubMed Web of Science ®Google Scholar
• Faguer S, Kamar N, Guilbeaud-Frugier C, et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation. 2007;83:1277–1280.
   PubMed Web of Science ®Google Scholar
• Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2009;9:1099–1107.
   PubMed Web of Science ®Google Scholar
• Kaposztas Z, Podder H, Mauiyyedi S, et al. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant. 2009;23:63–73.
   PubMed Web of Science ®Google Scholar
• Sautenet B, Blancho G, B√ºchler M, et al. One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial. Transplantation. 2016;100:391–399.
   PubMed Web of Science ®Google Scholar
• King’s College London, Collaborators: Medical Research Council, and Roche Pharma AG 2007. Study of Rituximab to Treat Chronic Renal Transplant Rejection. https://ClinicalTrials.gov/show/NCT00476164.
   Google Scholar
• Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2009;9:231–235.
   PubMed Web of Science ®Google Scholar
• Stewart ZA, Collins TE, Schlueter AJ, et al. Case report: eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant. Transplant Proc. 2012;44:3033–3036.
   PubMed Web of Science ®Google Scholar
• Gonz√°lez-Roncero F, Su√±Er M, Bernal G, et al. Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports. Transplant Proc. 2012;44:2690–2694.
   PubMed Web of Science ®Google Scholar
• Kocak B, Arpali E, Demiralp E, et al. Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports. Transplant Proc. 2013;45:1022–1025.
   PubMed Web of Science ®Google Scholar
• Orandi BJ, Zachary AA, Dagher NN, et al. Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation. Transplantation. 2014;98:857–863.
   PubMed Web of Science ®Google Scholar
• Kulkarni S, Kirkiles-Smith NC, Deng YH, et al. Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: a pilot randomized controlled trial. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2016 Aug 8. doi: 10.1111/ajt.14001. [Epub ahead of print].
   Google Scholar
• Pharmaceuticals A 2011. Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization. https://ClinicalTrials.gov/show/NCT01399593.
   Google Scholar
• Center, C.-S.M., and Pharmaceuticals, A. 2012. The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation. https://ClinicalTrials.gov/show/NCT02013037.
   Google Scholar
• Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111:1840–1847.
   PubMed Web of Science ®Google Scholar
• Dubey AK, Handu SS, Dubey S, et al. Belimumab: first targeted biological treatment for systemic lupus erythematosus. J Pharmacol Pharmacother. 2011;2:317–319.
   PubMedGoogle Scholar
• Pennsylvania, U.o., and Inc., H.G.S. 2010. Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant. https://ClinicalTrials.gov/show/NCT01025193.
   Google Scholar
• GlaxoSmithKline. 2013. A Study of Belimumab in the Prevention of Kidney Transplant Rejection. https://ClinicalTrials.gov/show/NCT01536379.
   Google Scholar
• Turnier JL, Brunner HI. Tocilizumab for treating juvenile idiopathic arthritis. Expert Opin Biol Ther. 2016;16:559–566.
   PubMed Web of Science ®Google Scholar
• Kang S, Tanaka T, Kishimoto T. Therapeutic uses of anti-interleukin-6 receptor antibody. Int Immunol. 2015;27:21–29.
   PubMed Web of Science ®Google Scholar
• Chen X, Das R, Komorowski R, et al. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood. 2009;114:891–900.
   PubMed Web of Science ®Google Scholar
• Vo AA, Choi J, Kim I, et al. A phase I/II trial of the interleukin-6 receptor-specific humanized monoclonal (tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients. Transplantation. 2015;99:2356–2363.
   PubMed Web of Science ®Google Scholar
• University of California, San Francisco. 2014. Tocilizumab for Renal Graft Inflammation. https://ClinicalTrials.gov/show/NCT02108600.
   Google Scholar
• Flechner SM, Mulgoankar S, Melton LB, et al. First-in-human study of the safety and efficacy of TOL101 induction to prevent kidney transplant rejection. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2014;14:1346–1355.
   PubMed Web of Science ®Google Scholar
• Vincenti F, Mendez R, Pescovitz M, et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2007;7:1770–1777.
   PubMed Web of Science ®Google Scholar
• Kawai T, Andrews D, Colvin RB, et al. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med. 2000;6:114.
   Web of Science ®Google Scholar
• Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin–dependent mechanism. Nat Med. 2002;8:247–252.
   PubMed Web of Science ®Google Scholar
• Goldwater R, Keirns J, Blahunka P, et al. A phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2013;13:1040–1046
   PubMed Web of Science ®Google Scholar
• Astellas Pharma Global Development, I., Kyowa Hakko Kirin Company, L., and Inc, A.P. 2013. A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients. https://ClinicalTrials.gov/show/NCT01780844.
   Google Scholar
• Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective fc receptor binding. Science. 2005;310:1510–1512.
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Rossi EA, Stein R, et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood. 2009;113:1062–1070.
   PubMed Web of Science ®Google Scholar
• Gunn BM, Alter G. Modulating antibody functionality in infectious disease and vaccination. Trends Mol Med. 2016;22:969–982.
   PubMed Web of Science ®Google Scholar
• Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115:4393–4402.
   PubMed Web of Science ®Google Scholar
• Taylor RP. Of mice and mechanisms: identifying the role of complement in monoclonal antibody-based immunotherapy. Haematologica. 2006;91:146a.
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, et al. Inhibitory fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6:443–446.
   PubMed Web of Science ®Google Scholar
• Kuo TT, Aveson VG. Neonatal fc receptor and IgG-based therapeutics. Mabs. 2011;3:422–430.
   PubMed Web of Science ®Google Scholar
• Laws LH, Parker CE, Cherala G, et al. Inflammation causes resistance to anti-cd20-mediated b cell depletion. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2016;16:3139–3149.
   PubMed Web of Science ®Google Scholar
• Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 2015;15:361–370.
   PubMed Web of Science ®Google Scholar